![]() ![]() Additionally, this research highlights the potential for researchers to utilize EHR-derived real-world data linked with genomic information to evaluate complex genomic biomarkers in a pan-tumor, real-world cohort to support the adoption of tumor-agnostic cancer treatments. File:MSI 2017 OPL (Tier 2) profileicon.png File:MSI 2017 TCL (Tier 1) profileicon.png File:MSI 2017 TCL (Tier 2) profileicon.png File:MSI 2018 100 Thieves. These insights provided supporting real-world evidence of the trial data in a rare, pan-tumor cohort where conducting additional trials would be challenging. ![]() With the advancements made in broad-based genomic sequencing and the ability to link this information with detailed clinical data obtained from electronic health records, researchers were able to look at the use of pembrolizumab in patients with MSI-H solid tumors across 36 different tumor types. 88 MSI Raider GE78 HX 13VH laptop review: 13th gen Core. 86 Lenovo ThinkPad T14 G3 review - Business laptop is worse with Intel and Nvidia. ![]() Using EHR-derived real-world data, this study examined characteristics and outcomes in a cohort of patients with solid tumors identified as MSI-H who received their first pembrolizumab treatment after May 2017. Deal Kaby Lake Laptop Geforce Gaming Windows AMD MSI. In May 2017, pembrolizumab monotherapy was granted the first tumor-agnostic, biomarker-based FDA approval in oncology for patients with microsatellite instability high (MSI-H) or mismatch repair (MMR) deficient tumors.Īs tumor-agnostic therapies are a new treatment paradigm, it is important to assess their use and effectiveness in routine clinical practice Flatiron Health's Tamara Snow discusses the background of this study and how patients with MSI-H solid tumors responded to pembrolizumab in real-world care. ![]()
0 Comments
Leave a Reply. |